
    
      The HELICOPTER-1 Trial is a single centre, randomized trial evaluating the feasibility of
      administration of Heliox for prevention of myocardial ischemia in patients undergoing cardiac
      surgery. Half of the study population will be randomly assigned to the receive cardioplegia
      enriched with a 70:30 (Helium:Oxygen) Heliox mixture, while the other half will be randomized
      to receive the current clinical standard of care (nitrogen and oxygen in cardioplegia).

      Subjects will be followed up daily during their post-operative course in hospital for
      clinical outcomes. A 30-day phone follow-up will be conducted for vital status and MI.
    
  